ALXN News and Press, Alexion Pharmaceuticals Inc. From 10/28/20

Alexion Pharmaceuticals (NASDAQ:ALXN) is scheduled to announce Q3 earnings results on Thursday, October 29th, before market open.The consensus EPS Estimate is $2.60 (-6.8% Y/Y) and the consensus Revenue Estimate is $1.43B (+13.5% Y/Y).Estimated Expenses on a non-GAAP basis R&D $268.6M and...

Most of us don't choose when to be sick, what illness will befall us, or what medicine we will take to recover. Thankfully, the pharmaceutical industry -- which is responsible for developing life-saving drugs -- never sleeps. While this sector has not escaped the COVID-19-induced economic c...

The market has shown strong support for Alexion YTD, where shareholders have enjoyed +64.28% since the selloff in March. Strong revenue growth on healthy margins paints the picture for periods to come, with equally as satisfying FCF positioning and capital structure. New level of ...

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results for the third quarter ended September 30, 2020 before the US financial markets open on October 29, 2020. Following the release of the financial results, Alexion management wil...

ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. Our diversified approach to portfolio construction, balan...

Top Medical Stocks To Watch This Week Be it good or bad times, people will still fall sick. This is often said in a time of a global recession. That is why medical stocks will always thrive during a recession. With the COVID-19 pandemic raging on, this is the reality we face tod...

Are These The Best Biotech Stocks To Buy This Month? A lot of attention is placed on biotech stocks right now. The reason is simply that they are at the forefront of medical discoveries. For the quality of life that we enjoy today, we can thank these biotech companies and their ...

ARGX is up nearly 15-fold since we first covered it positively in 2017. Now that it is approaching the market for the current lead indication, we still see some upside to the stock. We think it is a long term hold-able stock. For further details see: Argenx: Competitive ...

The FDA has approved Alexion Pharmaceuticals's (ALXN) Ultomiris (ravulizumab-cwvz) 100 mg/mL intravenous formulation for the treatment of adults with paroxysmal nocturnal hemoglobinuria ((PNH)) and atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediat...

– New 100 mg/mL formulation will reduce infusion time by approximately 60 percent, lessening the burden on patients – – ULTOMIRIS is approved for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) ...